• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Automated bladder cancer test receives FDA clearance

Article

Ikonisys Inc. has received FDA approval to market the oncoFISH bladder diagnostic application in the United States. In conjunction with the company’s proprietary Ikoniscope robotic digital microscopy platform, oncoFISH bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer.

Ikonisys Inc. has received FDA approval to market the oncoFISH bladder diagnostic application in the United States. In conjunction with the company’s proprietary Ikoniscope robotic digital microscopy platform, oncoFISH bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer.

oncoFISH bladder detects aberrations for chromosomes 3, 7, 9, and 17 in cells found in urine sediment to aid in the initial diagnosis of bladder cancer in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

The automated diagnostic platform is expected to significantly reduce the time required to process test results while improving the accuracy of bladder cancer diagnosis, according to the manufacturer.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.